e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Interstitial lung diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis
Yubiao Guo (Guangzhou, Guangdong Province, China), YuBiao Guo, Yifeng Luo, Daiyin Cao, Jingyu Chen
Source:
International Congress 2015 – Interstitial lung diseases II
Session:
Interstitial lung diseases II
Session type:
Thematic Poster Session
Number:
3849
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Yubiao Guo (Guangzhou, Guangdong Province, China), YuBiao Guo, Yifeng Luo, Daiyin Cao, Jingyu Chen. Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis. Eur Respir J 2015; 46: Suppl. 59, 3849
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The RANKL-OPG balance in pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Role of MUC1 in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Neutrophil chemotaxis and adhesion in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 108s
Year: 2001
Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 102s
Year: 2006
Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Year: 2013
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Role of IL-11 in vascular function of pulmonary fibrosis patients
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Role of interleukin-10 in idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 23: 179-180
Year: 2004
Modulation of fibroblast phenotype in idiopathic pulmonary fibrosis: Role of Nrf2
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Immunoproteasome expression in pulmonary fibrosis
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP)
Source: International Congress 2014 – ILDs 2
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept